TMOThermo Fisher Scientific
Price
+37%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, no red flags, demanding price, growth steady, the market undecided.
Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Thermo Fisher Scientific (TMO) reported revenue of $12.0B in Q2 2026 (quarter ended Jun 27, 2026), up 10% from the same quarter a year earlier. That came with net income of $1.74B (14% of revenue). For the full year FY2025, revenue was $44.6B (+3.9% year on year) and net income $6.70B. Its largest segment in Q2 2026 was Life Sciences Solutions at $1.06B, 38% of the disclosed total, ahead of Analytical Instruments at 30%. The next results filing is expected around Oct 21, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 23, 2026E-mail: sandy.pound@thermofisher.com.Earnings release · press release
- Apr 23, 2026E-mail: sandy.pound@thermofisher.com.Earnings release · press release
- Feb 12, 2026On February 12, 2026, Thermo Fisher Scientific Inc. (the “Company”) issued $1,000,000,000 aggregate principal amount of 4.215% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 aggregate principal amount of 4.550% Senior Notes due 2033 (the “2033 Notes”), $1,300,000,000 aggregate principal amount of 4.902% Senior …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $2.78BThe company’s own SEC segment disclosure.
- Life Sciences Solutions$1.06B38%
- Analytical Instruments$821.0M30%
- Laboratory Products And Biopharma Services$608.0M22%
- Specialty Diagnostics$290.0M10%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry